Get the Stockscreener App
3.23
0.00%
0.00
After Hours:
3.23
Savara Inc stock is traded at $3.23, with a volume of 2.19M.
It is up +0.00% in the last 24 hours and up +3.19% over the past month.
Savara Inc is a biopharmaceutical company. It is focused on rare respiratory diseases. The company's program, molgramostim nebulizer solution (molgramostim), is an inhaled granulocyte-macrophage colony-stimulating factor in Phase 3 development for autoimmune pulmonary alveolar proteinosis (aPAP). It has one segment specialty pharmaceuticals within the respiratory system.
See More
Previous Close:
$3.23
Open:
$3.2
24h Volume:
2.19M
Relative Volume:
1.53
Market Cap:
$554.33M
Revenue:
-
Net Income/Loss:
$-54.70M
P/E Ratio:
-11.54
EPS:
-0.28
Net Cash Flow:
$-51.36M
1W Performance:
+0.62%
1M Performance:
+3.19%
6M Performance:
-13.17%
1Y Performance:
-28.54%
1-Day Range:
$3.12
$3.325
1-Week Range:
$2.99
$3.395
52-Week Range:
$2.815
$5.70
Savara Inc Stock (SVRA) Company Profile
Name
Savara Inc
Sector
Industry
Phone
51285113796
Address
6836 BEE CAVE ROAD, AUSTIN, TX
Compare SVRA with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
SVRA
Savara Inc
|
3.23 | 554.33M | 0 | -54.70M | -51.36M | -0.33 |
|
VRTX
Vertex Pharmaceuticals Inc
|
397.27 | 102.31B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
701.85 | 77.13B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
623.82 | 37.30B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
245.44 | 31.66B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
113.08 | 27.11B | 3.30B | -501.07M | 1.03B | -2.1146 |
Savara Inc Stock (SVRA) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Nov-13-24 | Downgrade | Evercore ISI | Outperform → In-line |
| Feb-15-24 | Initiated | JMP Securities | Mkt Outperform |
| Nov-07-23 | Initiated | Guggenheim | Buy |
| May-16-23 | Upgrade | Jefferies | Hold → Buy |
| Mar-31-23 | Downgrade | Jefferies | Buy → Hold |
| Mar-16-21 | Initiated | Piper Sandler | Overweight |
| Mar-15-21 | Initiated | Oppenheimer | Outperform |
| Jun-13-19 | Reiterated | H.C. Wainwright | Buy |
| Jun-13-19 | Downgrade | JMP Securities | Mkt Outperform → Mkt Perform |
| Jun-13-19 | Downgrade | Ladenburg Thalmann | Buy → Neutral |
| Aug-13-18 | Resumed | ROTH Capital | Neutral |
| Jan-03-18 | Initiated | Ladenburg Thalmann | Buy |
| Sep-27-17 | Resumed | ROTH Capital | Buy |
| Sep-22-17 | Initiated | Jefferies | Buy |
| Sep-11-17 | Initiated | JMP Securities | Mkt Outperform |
View All
Savara Inc Stock (SVRA) Latest News
Wells Fargo Initiates Coverage of Savara (SVRA) with Overweight Recommendation - MSN
UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Acquires 6,141 Shares of Savara Inc (NASDAQ:SVRA) - Defense World
Savara: Rolling BLA Submission Of MOLBREEVI Generates Catalysts To Track (NASDAQ:SVRA) - Seeking Alpha
Savara (NASDAQ:SVRA) Now Covered by Analysts at Wells Fargo & Company - MarketBeat
Savara's SWOT analysis: rare disease biotech stock poised for growth By Investing.com - Investing.com Canada
Savara's SWOT analysis: rare disease biotech stock poised for growth - Investing.com
Savara (NASDAQ:SVRA) Shares Up 5.6%Time to Buy? - MarketBeat
BNP Paribas Financial Markets Purchases 18,534 Shares of Savara Inc (NASDAQ:SVRA) - Defense World
JMP Securities Reiterates "Market Outperform" Rating for Savara (NASDAQ:SVRA) - MarketBeat
Savara's MOLBREEVI Advances Toward First-Ever aPAP Treatment with FDA Rolling BLA Submission - StockTitan
Savara Announces Participation in the 43rd Annual J.P. Morgan Healthcare Conference - BioSpace
Savara to Present at J.P. Morgan Healthcare Conference: Rare Respiratory Disease Breakthroughs in Focus - StockTitan
Savara's CFO David Lowrance sells $83,277 in stock By Investing.com - Investing.com South Africa
The Manufacturers Life Insurance Company Acquires 3,706 Shares of Savara Inc (NASDAQ:SVRA) - Defense World
Savara director Hawkins sells $26,568 in stock By Investing.com - Investing.com Australia
Savara director Hawkins sells $26,568 in stock - Investing.com India
Savara's SWOT analysis: molgramostim's promise buoys stock amid challenges - Investing.com
Savara Inc (NASDAQ:SVRA) CEO Matthew Pauls Sells 54,702 Shares - MarketBeat
Savara's CFO David Lowrance sells $83,277 in stock - Investing.com
Savara CEO Matthew Pauls sells $180,828 in stock - Investing.com
Savara CEO Matthew Pauls sells $180,828 in stock By Investing.com - Investing.com Australia
Charles Schwab Investment Management Inc. Boosts Stake in Savara Inc (NASDAQ:SVRA) - MarketBeat
Charles Schwab Investment Management Inc. Buys 642,259 Shares of Savara Inc (NASDAQ:SVRA) - Defense World
Janus Henderson Group PLC Decreases Stock Position in Savara Inc (NASDAQ:SVRA) - MarketBeat
Wellington Management Group LLP Acquires 1,608,522 Shares of Savara Inc (NASDAQ:SVRA) - MarketBeat
XChain, VARA’s Exclusive Transaction Monitoring Partner, Readies Rollout for Regional and Global VASPs - GlobeNewswire Inc.
Savara Inc (NASDAQ:SVRA) Given Consensus Recommendation of "Moderate Buy" by Brokerages - MarketBeat
Intech Investment Management LLC Invests $174,000 in Savara Inc (NASDAQ:SVRA) - Defense World
Savara's SWOT analysis: molgramostim's promise lifts rare disease stock - Investing.com
Savara (NASDAQ:SVRA) Shares Down 3.2%Here's What Happened - MarketBeat
Savara Inc. Announces Stock Awards for New Employees - MSN
Savara Inc (NASDAQ:SVRA) Stock Holdings Lifted by Vestal Point Capital LP - MarketBeat
Connor Clark & Lunn Investment Management Ltd. Acquires 242,249 Shares of Savara Inc (NASDAQ:SVRA) - MarketBeat
Savara Grants 150,000 Share Inducement Awards to New Employees | SVRA Stock News - StockTitan
Savara Announces New Employment Inducement Grant - Business Wire
Savara to Present Phase 3 Trial Results for Breakthrough aPAP Treatment at BTS Meeting | SVRA Stock News - StockTitan
Jennison Associates LLC Acquires 1,001,296 Shares of Savara Inc (NASDAQ:SVRA) - MarketBeat
Independent Director of Savara Picks Up 4.5% More Stock - Simply Wall St
Savara Inc. Reports Third-Quarter Financial Results and Announces Key Regulatory Milestones - MSN
Insider Buying Alert: Joseph Mccracken Acquires 20,000 Shares of Savara Inc (SVRA) - GuruFocus.com
Savara director Joseph McCracken acquires $59,071 in common stock - Investing.com India
Savara director Joseph McCracken acquires $59,071 in common stock By Investing.com - Investing.com Canada
Director David Ramsay Acquires 100,000 Shares of Savara Inc (SVR - GuruFocus.com
Savara Inc director David Ramsay buys $287,600 in common stock - Investing.com
Savara Inc director David Ramsay buys $287,600 in common stock By Investing.com - Investing.com UK
Savara (NASDAQ:SVRA) Shares Down 8.5%Time to Sell? - MarketBeat
Prudential Financial Inc's Strategic Acquisition of Savara Inc S - GuruFocus.com
What is HC Wainwright's Estimate for Savara FY2024 Earnings? - MarketBeat
Evercore ISI Reiterates In-Line Rating for Savara (NASDAQ:SVRA) - Defense World
Savara (NASDAQ:SVRA) Reaches New 1-Year Low on Analyst Downgrade - MarketBeat
SVRA stock touches 52-week low at $3.27 amid market challenges - Investing.com India
Savara Inc Stock (SVRA) Financials Data
Revenue
Net Income
Cash Flow
EPS
Savara Inc Stock (SVRA) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Pauls Matthew | CHIEF EXECUTIVE OFFICER |
Dec 16 '24 |
Sale |
3.31 |
54,702 |
180,828 |
1,536,379 |
| Hawkins Richard J | Director |
Dec 16 '24 |
Sale |
3.32 |
8,000 |
26,569 |
67,241 |
2.88%
2.65%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):